• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NLS Pharmaceutics CEO Issues Letter to Shareholders

    6/16/25 7:00:00 AM ET
    $NLSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NLSP alert in real time by email

    ZURICH , June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.

    NLS Pharmaceutics Logo

     

    Dear Shareholders,

    We are delighted to share a summary of NLS Pharmaceutics' achieved milestones since the fourth quarter of 2024. Here's a snapshot of our progress and what lies ahead:

    1. Completion of Major Financing Events

    • During the first quarter of 2025, we initially closed two equity financing transactions, resulting in aggregate gross proceeds of $2.5 million, priced at $3.10 and $1.65 per share at a premium to the market share price as of the date of the transactions, representing a premium of 48% and 10%, respectively.
    • In addition, we signed a $25 million equity facility commitment. The potential proceeds from this facility are earmarked to support the merger with Kadimastem Ltd. (TASE: KDST). ("Kadimastem") and the Company's advance clinical programs.

    Since we first announced the proposed merger with Kadimastem, we have raised more than $6 million in the aggregate to support the pending transaction and the combined company's clinical trials post-merger. Moreover, we have converted all of the Company's outstanding liabilities into equity, reflecting a strong balance sheet of a company free of debt.  These financing events have not only strengthened our balance sheet, but have extended our cash runway, enabling us to pursue continued research & development efforts and proceed with the execution of the merger.

    2. Positive Clinical and Preclinical Developments

    • In February 2025, we announced encouraging preclinical data for AEX–2, further validating our dual orexin receptor agonist platform ("DOXA") for central nervous systems ("CNS") disorders.
    • In February 2025, we announced that Kadimastem and iTolerance successfully completed a Pre-IND Meeting with the U.S. Food and Drug Administration (FDA) for its Type 1 Diabetes Treatment, representing a significant asset for the merged company, NewcelX.
    • In April 2025, positive results from Study KO–943 revealed that Mazindol ER significantly reduced fentanyl–induced reward behaviors in animal models. These results represent important proof–points for both safety and therapeutic potential as we prepare for next–stage trials.

    3. Merger with Kadimastem — Strategic Synergy in Action

    • In January 2025, following the approval by the board of directors of NLS and Kadimastem, Kadimastem's shareholders overwhelmingly approved the merger, a critical step in closing the merger and in bringing together the complementary strengths of Kadimastem and NLS.
    • Amendments to the Registration Statements on Form F–4 were filed, paving the way for the final NLS shareholder vote.

    Today, the merger process is progressing. We target completing the merger in early Q3 2025, subject to requirements set forth by all regulatory agents.

    Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem, said, "We are excited about the upcoming merger, which aligns with our strategic goals and will enable us to provide comprehensive therapeutic options for patients. By joining forces, we can better serve those with diabetes and combat its complexity. This merger demonstrates a commitment to innovation, patient care, and long-term value. Together, we aim to improve the lives of diabetics and patients with related conditions. We are committed to ensuring a smooth integration process as we move forward, following the completion of the merger. In addition to the equity investment, we believe the committed equity facility agreement of $25 million will enhance the combined company's balance sheet and could provide flexibility to support future pipeline development."

    4. What the Combined Company Will Look Like

    • The combined entity will be named NewcelX and intends to be a Nasdaq–listed clinical–stage biotech with a robust pipeline spanning neurodegenerative disease (AstroRx® for amyotrophic lateral sclerosis ("ALS") in a Phase IIa stage), diabetes (IsletRx), and CNS disorders via the DOXA platform.
    • Shareholders are expected to continue to benefit from our legacy assets—notably Mazindol ER—through contingent value rights subject to potential future sales.

    5. Looking Ahead

    As we approach the anticipated closing of the merger, we are preparing to rapidly initiate:

    • Phase IIa multi–site clinical trial for AstroRx®, targeting ALS.
    • Phase I study for IsletRx in Type I diabetes.
    • Continued preclinical progression of AEX–2/AEX–41 toward late–stage development (e.g., narcolepsy, neurodegeneration).

    Our anticipated merger with Kadimastem is expected to mark a transformational pivot—uniting our proprietary DOXA platform and the cell–therapy assets under one roof. With a fortified capital structure, and a unified board guiding our research and development direction, we are strategically positioned for meaningful value creation.

    In Conclusion

    Thanks to your trust and resilience, NLS stands on the edge of a powerful new chapter. We anticipate the closing of the merger to occur in the near future, followed by an energized integration phase and accelerated clinical momentum.

    Thank you for your enduring support. Together, we will accelerate development, diversify our pipeline, and enhance long-term shareholder value.

    With optimism,

    Alexander C. Zwyer

    Chief Executive Officer

    NLS Pharmaceutics (NASDAQ:NLSP)

    About NLS Pharmaceutics Ltd.

    NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.

    About Kadimastem

    Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

    IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

    Social Media: LinkedIn, X, Facebook, Instagram

    Safe Harbor Statement

    This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements when they discuss the expected closing, and the timing of the closing, of the transaction and the potential benefits of the transaction to NLS and Kadimastem and their respective shareholders, including value creation for shareholders, as well as the expected strategic position of the combined company following the Merger, if completed, and the plan to prepare and initiate a Phase IIa multi-site clinical trial of AstroRx®, Kadimastem's product candidate for Amyotrophic Lateral Sclerosis (ALS). These forward-looking statements and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks related to the companies' ability to complete the Merger on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely, or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses resulting from the transaction and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Merger; changes in technology and market requirements; either or both companies may encounter delays or obstacles in launching and/or successfully completing their clinical trials; the companies' products may not be approved by regulatory agencies; their technologies may not be validated as they progress and their methods may not be accepted by the scientific community; either of both of the companies may be unable to retain or attract key employees whose knowledge is essential to the development of their products; unforeseen scientific difficulties may develop with the products being advanced by the companies; their products may wind up being more expensive than anticipated; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; the companies' patents may not be sufficient; their products may harm recipients; changes in legislation may adversely impact either or both of the companies; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of candidate products to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, neither Kadimastem nor NLS undertakes any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS's annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC"), which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC, including under the heading "Risk Factors" in NLS's registration statement on Form F-4, filed with the SEC on December 27, 2024.

    No Offer or Solicitation

    This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

    Additional Information about the Transaction and Where to Find It

    In connection with the proposed transaction, NLS filed a registration statement on Form F-4 on December 30, 2023, including a proxy statement/prospectus, with the SEC (the "F-4 Registration Statement"), and subsequent Amendments to the F-4 Registration Statement on March 3, 2025, March 31, 2025, and June 9, 2025. NLS may also file other relevant documents with the SEC regarding the proposed transaction. This document is not a substitute for the proxy statement/prospectus or any other document that NLS may file with the SEC. The proxy statement (if and when available) will be mailed or delivered to shareholders of NLS and Kadimastem. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other documents containing important information about NLS and Kadimastem and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on NLS's website at www.nlspharma.com.

    Participants in the Solicitation

    NLS, Kadimastem, and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders in respect of the proposed transaction. Information about the directors and executive officers of NLS, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in NLS's Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which was filed with the SEC on May 16, 2025. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from NLS Pharmaceutics using the sources indicated above.

    NLS Contacts:

    [email protected]

    www.nlspharma.com

    Kadimastem Contacts:

    Sarah Bazak, Investors relations

    [email protected]

    www.kadimastem.com

    Logo: https://mma.prnewswire.com/media/2637716/5243216/NLS_Pharmaceutics_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/nls-pharmaceutics-ceo-issues-letter-to-shareholders-302482244.html

    SOURCE NLS Pharmaceutics Ltd.

    Get the next $NLSP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NLSP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NLSP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

      Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed $3 million equity financing of preferred shares (or equivalents) and warrants from March 2025. Pursuant to the second closing, the Company agreed to issue 606,061 preferred shares (or equivalent) at a conversion price of $1.65 per share, representing a 10% premium to the market share

      6/30/25 7:00:00 AM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NLS Pharmaceutics CEO Issues Letter to Shareholders

      ZURICH , June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.   Dear Shareholders, We are delighted to share a summary of NLS Pharmaceutics' achieved milestones since the fourth quarter of 2024. Here's a snapshot of our progress and what lies ahead: 1. Completion of Major Financing Events During the first quarter of 2025, we initially closed two equity financing transactions, resulting in aggregate gross proceeds of $2.5 million, priced at $3.10 and $1.65 per share at a premium to the market share p

      6/16/25 7:00:00 AM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

      Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics Favorable results support potential expansion into high-value markets beyond ADHD and narcolepsy ZURICH, April 15, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced positive results from Study KO-943, a preclinical investigation evaluating the efficacy of Mazindol in mitigating fentanyl-induced conditioned place preference (CPP) in mice. The study, conducted by Key-Obs SAS, a leading precl

      4/15/25 9:00:00 AM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brookline Capital initiated coverage on NLS Pharmaceutics with a new price target

      Brookline Capital initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $12.00

      3/12/21 12:01:52 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on NLS Pharmaceutics with a new price target

      Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00

      3/9/21 8:09:21 AM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on NLS Pharmaceutics with a new price target

      Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00

      3/3/21 8:36:01 AM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLSP
    SEC Filings

    See more
    • SEC Form 6-K filed by NLS Pharmaceutics Ltd.

      6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

      7/1/25 4:30:56 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by NLS Pharmaceutics Ltd.

      425 - NLS Pharmaceutics Ltd. (0001783036) (Subject)

      7/1/25 4:02:09 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by NLS Pharmaceutics Ltd.

      6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)

      7/1/25 4:01:07 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLSP
    Leadership Updates

    Live Leadership Updates

    See more
    • NLS Pharmaceutics Announces Election of Additional Board Members

      Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disordersProfessor Florence Allouche Aknin, PharmD, MBA, is a professor at University Paris City, specializing in pharmaceutical innovation, entrepreneurship and fundraisingZURICH, SWITZERLAND / ACCESSWIRE / November 28, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that, subject to final ap

      11/28/23 7:30:00 AM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NLS Pharmaceutics CEO Issues Letter to Shareholders

      ZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:NLS Pharmaceutics CEO Issues Letter to ShareholdersTo our Shareholders and Friends,Though we may have been quiet recently, I wanted to assure you that the team here at NLS has been very busy behind the scenes ensuring that we realize our vision of awakening a brighter future for pa

      8/28/23 7:30:00 AM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

      ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Keith Harrison Dewedoff has been appointed to the position of Interim Chief Financial Officer ("CFO"). A versatile strategic leader within healthcare, Mr. Dewedoff brings more than 20 years of experience in the life sciences industry, ranging from biotech venture-backed start-ups to commercial publicly traded companies. Mr. Dewedoff also serves as a CFO and Advisor fo

      5/8/23 8:30:00 AM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NLS Pharmaceutics Ltd.

      SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

      11/21/24 4:01:13 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NLS Pharmaceutics Ltd.

      SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

      11/14/24 7:27:23 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by NLS Pharmaceutics Ltd.

      SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)

      11/14/24 3:33:43 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care